TNF and inflammatory bowel disease: The co-occurrence of SpA and IBD has been extensively documented, reflecting shared pathogenic mechanisms that result in shared treatment targets, such as biologic agents—anti-tumor necrosis factor (TNF) agents, and small molecules such as JAK inhibitors.